1.Product:ON101
2.Mass production date:NA
3.Effect on company finances and business:
(1)New drug name or code:ON101
(2)Purpose:Treatment of Diabetic foot ulcer.
(3)Planned development stages：The second phase 3 clinical trial (ON101CLCT04)in the US, and other exploratory studies for new
   indications.
(4)Current development stage:
   A.File application/approved/disapproved/Each of clinical trials (include interim analysis): New drug approval is obtained from The Ministry of
     Health and Welfare Food and Drug Administration (TFDA) and its official drug certificate will be notified for receipt.
   B.Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant
     sense,the risks and the associated measures the Company may occur: NA
   C.After obtaining official approval or the results (include interimanalysis) of statistically significant sense, the future strategy:
     Product launch for commercialization is proceeding including drug listing plan in hospitals, sales training and strategic collaboration
     with medical associations and societies.
   D.Accumulated investment expenditure incurred:No disclosure of the investment expenditure at the moment in consideration of the future
     marketing strategies to protect the company and investors interests.
(5)Upcoming development plan:
   A.Scheduled completion date:2-3 years after initiation of the second  phase 3 trial in the US.
   B.Estimate responsibilities:After product commercialization, the company shall pay the licenser a certain percentage of royalties according to
      the agreement.
(6)Market:According to the statistics of the International Diabetes Federation, the total number of diabetic patients worldwide was 425
    million and will reach 629 million in 2045. Among those patients, 19–34% will encounter a foot ulcer during their lifetime. Some of the patients
    would end up with amputation and the 5-year survival of the amputees is about 60%, which indicates DFU is a serious complication causing death
    and disability in diabetes patients. According to the 2018 Diabetes Clinical Care Guidelines, there are about 22,000 diabetic foot patients
    being hospitalized in Taiwan per year, of which about 6,700 proceeded to amputation. Further, based on a retrospective analysis of an
    international journal, Diabetes Care in May 2020 (Diabetes Care. 2020;43 (8):1732-1740), the average annual treatment cost for a DFU in Taiwan is
    NT$140,000, and the average annual cost of an amputation is about NT$390,000. It shows that the medical burden caused by DFU is tremendous
    that not only affects patients and their families, but also imposes a heavy burden on the government and society.
4.Any other matters that need to be specified:
(1)According to Article 2 under Guidelines by Taipei Exchange on the Material Information Announced by Listed and OTC Companies, new drug development
   companies shall make public announcement when filing application for clinical trials to domestic or overseas regulatory authorities, receiving
   approval or disapproval, obtaining the statistical date of endpoints in each clinical trial (including interim analysis), or receiving approval or
   disapproval on drug license application.
(2)It takes considerable time and expenses to develop a new drug of which success can’t be guaranteed. Investors shall bear such investment risk
   that warrants careful assessment before making investment decisions.